Results from the phase II CABOSUN clinical trial, showing cabozantinib to be superior to sunitinib as first-line treatment for advanced kidney cancer, were presented at the European Society for Medical Oncology (ESMO) congress in Copenhagen this week. Read more
Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for [...]
Many people have misconceptions about clinical trials. These images help to correct these misconceptions..
by Deb Maskens, Kidney Cancer Canada The American Society of Clinical Oncology (ASCO) held its annual Genitourinary (GU) Cancers Symposium in San Francisco from January 7-9. The theme of this year’s Symposium was “Patient-Centric Care: Translating Research to Results”. The [...]
Has Immune Checkpoint blockade re-established immunotherapy as a Key Pillar of Kidney cancer care? A panel led by Dr. Michael Atkins discusses the current state of immuno-oncology for kidney cancer.
IKCC launches an educational website for immuno-oncology for kidney cancer. Powerful Patient interviews Deb Maskens about this effort and its goals.
